Pfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China, in a deal that underscores ...

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

Pfizer also plans to make a $100 million equity investment in the Chinese biotechnolgoy company after the transaction closes, ...

Pfizer (NYSE:PFE) has signed an exclusive global licensing deal with China’s 3SBio for the development of its cancer drug ...

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Pfizer Inc. (NYSE:PFE) announced it had entered into a licensing agreement valued at approximately $6 billion with Chinese ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...

May 19 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said it would license an experimental cancer treatment from China's 3SBio Inc (1530.HK), opens new tab, paying $1.25 billion upfront ...

The pharma giant entered an exclusive agreement with the Chinese biotech to gain rights to a cancer bispecific drug candidate.

US drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.